Drug Type Bispecific antibody |
Synonyms- |
Target |
Mechanism Tie-2 agonists(TEK receptor tyrosine kinase agonists), VEGF inhibitors(Vascular endothelial growth factor inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetic macular oedema | Preclinical | US | 30 Jan 2022 | |
Diabetic Neuropathies | Preclinical | US | 30 Jan 2022 | |
Retinal Diseases | Preclinical | - | - | |
Retinal Diseases | Preclinical | - | - |